European Commission approval of Wegovy pill lifts Novo Nordisk stock toward $49.9

Traders Union
All News
Financial News
Novo Nordisk rises 1.77% after EU approval

Highlights

Novo Nordisk gained EU approval for Wegovy, the first oral GLP-1 weight-loss therapy, expanding its obesity market dominance.
A global restructuring involving 9,000 job cuts aims to focus resources on diabetes and obesity, supporting long-term growth.
NVO/USD trades in a strong bullish trend with high probability of further gains; expected range is $49.90 to $53.02.

Revenue prospects expand as EU approves oral Wegovy, layoffs signal shift

Novo Nordisk has secured European Commission approval for its once-daily Wegovy pill, making it the first oral GLP-1 weight-loss treatment available to adults in the European Union with obesity or overweight and at least one weight-related health condition, according to Indiamedtoday. This regulatory milestone opens significant new revenue streams in a major global market and strengthens the company’s lead in obesity therapies. In addition, Novo Nordisk’s announced global restructuring, including 9,000 job cuts, is set to streamline operations and channel resources toward its diabetes and obesity businesses, aiming to enhance long-term growth prospects.

Support zones and bullish momentum accentuate caution near overbought signals

On the technical front, NVO trades above the MA-20 ($50.43) and MA-50 ($49.69) on the H1 chart, while also remaining above the MA-200 ($47.42) on the daily timeframe. The Ichimoku Kijun provides immediate support at $50.03. Momentum indicators on H1 show the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both on Buy, while the Relative Strength Index (RSI) stands at 67.8, signaling strong bullish momentum yet nearing overbought territory. The Commodity Channel Index (CCI) is bullish, Stochastic RSI is Neutral, and Bull/Bear Power is in Overbought, confirming buyer dominance intraday. The Awesome Oscillator is Neutral, and some oscillators produce mixed signals, highlighting a need for caution near the session’s highs.

Price consolidation likely as breakout risks favor further upside

In the near term, the expected trading range for NVO is $49.9 to $53.02, reflecting the typical volatility band relative to current levels. The baseline scenario anticipates price consolidation within this range. Should bullish momentum persist and a breakout occur above upper resistance, an advance toward new highs is likely. Conversely, a move below the immediate support at $50.03 would increase the risk of deeper pullbacks, though current probabilities favor further gains.

Viktoras Karapetjanc, expert at Traders Union, sees Novo Nordisk’s regulatory milestone and focused restructuring as strong positives for future growth. He believes the European approval of the Wegovy pill materially expands addressable markets. The analyst notes bullish momentum is reinforced by technical indicators, though some signals suggest caution near overbought zones. For now, Karapetjanc expects ongoing strength as long as NVO holds above immediate support. "With Novo Nordisk breaking new ground in obesity treatments and streamlining its core operations, the bullish trend is well-supported by both fundamentals and market sentiment."

Earlier, analysts noted that Novo Nordisk’s ongoing share repurchases and clinical expansion efforts had reinforced a broadly positive outlook for the stock. The latest regulatory approval for oral Wegovy in Europe and operational restructuring not only strengthens this constructive stance but also introduces new catalysts, with traders watching for a potential breakout should momentum persist above the current consolidation range.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.